Compare Check Point Software Technologies Ltd (CHKP) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs ClearPoint Neuro Inc — how do they compare? Check Point Software Technologies Ltd trades at $129.28 (market cap $13.18B), while ClearPoint Neuro Inc trades at $15.3 (market cap $454.21M). The key difference: Check Point Software Technologies Ltd is far larger — about 29× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | CLPT | |
|---|---|---|
Market Cap | $13.18B | $454.21M |
Sector | Technology | Health |
52-Week High | $206.91 | $29.60 |
52-Week Low | $112.47 | $8.66 |
Enterprise Value | $12.88B | $488.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHKP trades at $129.29, down 1.41% today, with a bearish technical signal as it hovers near support at $128. The stock shows strong fundamentals with a P/E of 13.24, net income margin of 37.93%, and consistent earnings beats in recent quarters. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a consensus price target of $146.92, but near-term risks include competitive pressures and margin declines. Upside depends on AI-driven revenue acceleration in 2027, while downside is capped by solid cash flow and profitability.
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
